Filtered By:
Infectious Disease: COVID-19

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 15791 results found since Jan 2013.

Pronounced State Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020)
CONCLUSIONS: The COVID-19 pandemic exacerbated state-level disparities in buprenorphine prescribing for OUD among Medicaid patients. Legislation expanding buprenorphine waivered providers and Medicaid expansion may have contributed to the statistically significant changes in state buprenorphine prescriptions.PMID:37650858 | DOI:10.15288/jsad.22-00373
Source: Journal of Studies on Alcohol and Drugs - August 31, 2023 Category: Addiction Authors: Sydney R Dana Stephanie D Nichols Kenneth L McCall Brian J Piper Source Type: research

Presence of SARS-CoV-2 in middle ear fluid and characterization of otitis media with effusion in COVID-19 patients
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus and the cause of coronavirus disease 2019 (COVID-19), a highly infectious respiratory illness characterized by fever, coughing, sore throat, fatigue, headache, muscle pain, and hemoptysis [1-3]. There has been an increased attention to otologic symptoms in COVID-19 patients [4, 5]. Upper respiratory tract infections often result in middle ear infections, although there is limited evidence of a causal relationship of COVID-19 and otitis media with effusions (OME) [6].
Source: International Journal of Infectious Diseases - August 31, 2023 Category: Infectious Diseases Authors: Yue Fan, Ruzhen Gao, Yingying Shang, Xu Tian, Yang Zhao, Xingming Chen Source Type: research

Long COVID Recovery Remains Rare. Doctors Are Struggling to Understand Why
Since August 2020, David Putrino, director of rehabilitation innovation at New York’s Mount Sinai Health System, has helped treat more than 3,000 people with Long COVID. These patients, in his experience, fit into one of three groups. [time-brightcove not-tgx=”true”] A small number, no more than 10%, have stubborn symptoms that don’t get better, no matter what Putrino and his team try. A big chunk see some improvement, but remain sick. And about 15% to 20% report full recovery—an elusive benchmark that Putrino greets with cautious optimism. “I call it ‘fully recovered for n...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

IJERPH, Vol. 20, Pages 6678: Factors Associated with Long COVID-19 in a French Multicentric Prospective Cohort Study
Conclusions: This study showed that some patients experienced persistent clinical symptoms one year after COVID-19 onset that were associated with some determinants at the acute phase/stage.
Source: International Journal of Environmental Research and Public Health - August 29, 2023 Category: Environmental Health Authors: Nagham Khanafer Laetitia Henaff Sabrina Bennia Anne Termoz Roland Chapurlat Vanessa Escuret Mathilde Proriol Florence Duvert Camille Mena Catherine Planckaert Nad ège Trehet-Mandez Mitra Saadatian-Elahi Philippe Vanhems Tags: Article Source Type: research

Viruses, Vol. 15, Pages 1828: Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18 & ndash;60 and 60+ Age Cohorts
In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels.
Source: Viruses - August 29, 2023 Category: Virology Authors: Ilya V. Gordeychuk Liubov I. Kozlovskaya Aleksandra A. Siniugina Nadezhda V. Yagovkina Vladimir I. Kuzubov Konstantin A. Zakharov Viktor P. Volok Maria S. Dodina Larissa V. Gmyl Natalya A. Korotina Rostislav D. Theodorovich Yulia I. Ulitina Dmitry I. Vovk Tags: Article Source Type: research

The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers
CONCLUSIONS: The prevalence of SIRVA is estimated at 3% in the adult working population. Signs and symptoms of SIRVA are variable in severity, localization and timing. Soft-tissue abnormalities is the most common clinical sign. This study contributes to clinician's knowledge on SIRVA, aiding in early recognition and treatment, which are imperative for prevention of persistent and severe shoulder pathology.PMID:37635003 | DOI:10.1016/j.vaccine.2023.08.043
Source: Vaccine - August 27, 2023 Category: Allergy & Immunology Authors: Esther R C Janssen Astrid Z van Montfoort Freek Hollman Frederik O Lambers Heerspink Source Type: research